Deadline Approaching: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

Core Viewpoint - Soleno Therapeutics, Inc. is facing a class action lawsuit due to allegations of securities fraud related to its drug DCCR, with significant stock price declines following negative reports and disclosures [1] Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Soleno common stock between March 26, 2025, and November 4, 2026, with a deadline to file a lead plaintiff motion by May 5, 2026 [1] - The lawsuit alleges that Soleno made materially false and misleading statements regarding the safety and efficacy of DCCR, failing to disclose significant safety concerns and risks associated with the drug [1] - Following the publication of a critical report by Scorpion Capital, Soleno's stock price dropped significantly, including a decline of $9.27 (11.98%) to $68.09 on August 18, 2025, and a further drop of $16.98 (26.59%) to $46.87 on November 5, 2025 [1] Group 2: Financial Impact - The report by Scorpion Capital raised concerns about the clinical trial conduct and safety of DCCR, leading to a disruption in its launch trajectory and a decrease in patient start forms [1] - The stock price fell by $13.49 (19.21%) to $56.72 after a patient death was disclosed on September 10, 2025, indicating a direct financial impact on investors [1] - The lawsuit claims that the company's positive statements about its business and prospects were misleading and lacked a reasonable basis, contributing to investor losses [1]